ANAPTYSBIO, INC

AnaptysBio, Inc. is a clinical-stage biotechnology company focused on developing innovative immunology therapeutics for autoimmune and inflammatory diseases. The company's core business model involves generating revenue through financial collaborations for out-licensed therapeutic antibodies and advancing its wholly-owned clinical-stage pipeline. Revenue is recognized from milestones and royalties from collaborations, as well as license and transition services. The company is currently exploring a separation of its business into two independent, publicly traded companies: one focused on managing existing royalty streams ("Royalty Management Co") and another ("Biopharma Co") dedicated to the development and commercialization of its innovative therapeutics ¹.

The company's wholly-owned clinical-stage pipeline includes rosnilimab, ANB033, and ANB101. Rosnilimab is an IgG1 antibody targeting pathogenic T cells for autoimmune and inflammatory diseases, having completed a Phase 2b trial for moderate-to-severe rheumatoid arthritis (RA) ². ANB033 is a CD122 antagonist in a Phase 1b trial for celiac disease (CeD) and eosinophilic esophagitis (EoE) ³. ANB101 is a BDCA2 modulator antibody in a Phase 1a trial for autoimmune and inflammatory diseases ⁴.

In terms of product and service lines, the company's collaborative programs include an immuno-oncology-focused collaboration with GSK and a license agreement with Vanda Pharmaceuticals Inc. Under the GSK collaboration, Jemperli (dostarlimab-gxly), a PD-1 antagonist antibody, has received multiple FDA and EMA approvals for various endometrial cancer indications ⁵. GSK reported $1.1 billion in sales for Jemperli for the year ended December 31, 2025, representing over 80% sales growth compared to $598.0 million in 2024 ⁶. The Vanda collaboration involves an exclusive global license for imsidolimab (IL-36R antagonist mAb), which has completed two registration-enabling global Phase 3 trials for generalized pustular psoriasis (GPP) ⁷. Vanda submitted a BLA for imsidolimab in GPP in December 2025, with an FDA target action date of December 12, 2026 ⁸.

For the fiscal year ended December 31, 2025, AnaptysBio reported total collaboration revenue of $234.6 million ⁹, an increase from $91.3 million in 2024 ¹⁰. The company incurred a net loss of $13.2 million ¹¹ for the year, compared to a net loss of $145.2 million in 2024 ¹². Basic and diluted EPS for 2025 was $(0.46) ¹³, an improvement from $(5.12) in 2024 ¹⁴. Research and development expenses decreased to $136.0 million in 2025 ¹⁵ from $163.8 million in 2024 ¹⁶. General and administrative expenses increased to $50.7 million in 2025 ¹⁷ from $42.4 million in 2024 ¹⁸. Non-cash interest expense for the sale of future royalties increased to $79.9 million in 2025 ¹⁹ from $50.1 million in 2024 ²⁰. Interest income decreased to $13.5 million in 2025 ²¹ from $19.8 million in 2024 ²². As of December 31, 2025, cash, cash equivalents, and investments totaled $311.6 million ²³. The company had an accumulated deficit of $772.6 million as of December 31, 2025 ²⁴.

Year-over-year, collaboration revenue increased by $143.3 million ²⁵, driven by an $85.0 million increase in Jemperli sales milestones, a $48.6 million increase in Jemperli and Zejula royalty revenue, and a $9.7 million increase in Vanda license and transition services revenue ²⁶. Research and development expenses decreased by $27.8 million ²⁷, primarily due to a $21.6 million decrease in clinical expenses and a $12.0 million decrease in outside services for manufacturing expenses, partially offset by a $5.5 million increase in salaries and related costs ²⁸. General and administrative expenses increased by $8.3 million ²⁹, mainly due to a $5.2 million increase in legal expenses and a $2.5 million increase in transaction costs related to the Vanda License Agreement ³⁰.

During 2025, the company announced initial data from rosnilimab's Phase 2b clinical trial for moderate-to-severe rheumatoid arthritis, which achieved its primary endpoint of reduction of disease activity using DAS28-CRP score and ACR20 response at Week 12 in all three doses compared to placebo ³¹. ANB033 healthy volunteer Phase 1a trial top-line data demonstrated no safety concerns and a rapid and sustained pharmacokinetic profile ³². The company initiated a Phase 1 clinical trial of ANB101 in healthy volunteers in March 2025 ³³. In October 2025, GSK terminated the TIM-3 antagonist antibody development program, with all rights reverting to AnaptysBio ³⁴. On January 31, 2025, the company entered into an Exclusive License Agreement with Vanda for imsidolimab, receiving an upfront payment of $10.0 million and a $5.0 million payment for existing drug supply ³⁵. In December 2025, Vanda submitted a BLA to the U.S. FDA for imsidolimab in GPP ³⁶. The Board of Directors approved plans to explore separating the business into two independent, publicly traded companies in September 2025 ³⁷. In November 2025, the Board of Directors approved a common stock repurchase program authorizing $100.0 million in repurchases, supplementing a previous $75.0 million authorization from March 2025 ³⁸. During 2025, the company purchased 3.4 million shares at a cost of $68.6 million under this program ³⁹. The company also filed a Verified Complaint in Delaware Chancery Court on November 20, 2025, alleging material breach of the Collaboration Agreement by Tesaro and tortious interference by GSK ⁴⁰.

The company expects to complete the proposed separation of its business into two independent, publicly traded companies in the second quarter of 2026 ⁴¹. Upon completion, the clinical-stage biotechnology company is intended to launch with adequate capital to fund operations for at least twelve months after the separation date ⁴². The proposed separation is anticipated to be a taxable event, with a focus on minimizing overall corporate and shareholder-level taxes ⁴³.

Regarding growth areas, the company's strategy includes enabling broad development of its autoimmunity and inflammation-focused portfolio, generating translational and clinical data to characterize its molecules and optimize their development, innovating in clinical development and execution to achieve proof-of-concept and execute registrational studies, and facilitating global commercialization while retaining rights in key markets ⁴⁴. The company also plans to continue leveraging its research expertise to identify, license, and innovate on potentially best-in-class antibodies against high-value immunological targets ⁴⁵.

Operationally, the company expects its research and development expenses to be consistent for the foreseeable future as it continues to advance its product candidates ⁴⁶. General and administrative expenses may increase due to stock compensation, legal, auditing, filing fees, insurance premiums, investor relations, and general compliance and consulting expenses ⁴⁷. The company's internal manufacturing capabilities include non-cGMP antibody and reagent production for characterization and preclinical assessment, but it relies on third-party manufacturers for cGMP compliant cell lines and drug substance/product for clinical trials and commercial products ⁴⁸.

For capital allocation, the company's primary uses of capital are expected to continue to be third-party clinical and preclinical research and development services, including manufacturing, laboratory and related supplies, compensation and related expenses, legal, patent and other regulatory expenses, and general overhead costs ⁴⁹. The company's Board of Directors approved a common stock repurchase program in November 2025, authorizing $100.0 million in repurchases, which expires on March 31, 2026 ⁵⁰. As of December 31, 2025, approximately $106.4 million remained available for future stock repurchases under this program ⁵¹. The company does not intend to pay dividends on its common stock ⁵².

Investing in the company's common stock involves a high degree of risk, including the potential for product candidates to fail or suffer delays in development, which could adversely affect their commercial viability. Clinical trials may reveal significant adverse events, toxicities, or other side effects, inhibiting regulatory approval or market acceptance. The company and its collaborators may be unable to obtain or experience delays in obtaining required regulatory approvals in the U.S. or foreign jurisdictions, materially impairing commercialization and revenue generation. Even if approved, products will be subject to significant post-marketing regulatory requirements. The company faces substantial competition from major pharmaceutical and biotechnology companies with greater resources and expertise. Product candidates may not achieve adequate market acceptance among physicians, patients, and payors. The company currently lacks a marketing and sales force, and failure to establish one or secure third-party agreements could hinder commercialization. Manufacturing biologics is complex, and reliance on third-party manufacturers, including those in China, poses risks of production difficulties, supply chain disruptions, and increased costs due to macroeconomic conditions or trade policies. The proposed separation of the business into two independent companies is subject to various risks and uncertainties, may not be completed as contemplated, and will involve significant time, effort, and expense. Dependence on existing collaborations, particularly with GSK, and the ability to establish new ones, is critical. The company is currently involved in litigation with GSK regarding the Collaboration Agreement, which could have a materially negative impact on its rights and financial position. Inability to obtain or protect intellectual property rights globally could impair competitive positioning. The company must attract and retain highly skilled employees, and its operations are vulnerable to interruptions from natural disasters, public health events, and cybersecurity threats. The market price of the company's stock has been and may continue to be volatile. The company has a history of operational losses and will require additional capital, which may not be available on acceptable terms, potentially delaying or discontinuing product development. The company's ability to use net operating loss carryforwards to offset taxable income could be limited by ownership changes.

Management's message to shareholders emphasizes the company's focus as a clinical-stage biotechnology company dedicated to delivering innovative immunology therapeutics for autoimmune and inflammatory diseases. They highlight the ongoing clinical development of rosnilimab, ANB033, and ANB101, alongside the financial collaborations for out-licensed antibodies Jemperli and imsidolimab. A key strategic priority is the proposed separation of the business into two independent, publicly traded companies, expected to be completed in the second quarter of 2026 ⁴¹, with the clinical-stage biotechnology company launching with adequate capital to fund operations for at least twelve months after the separation date ⁴². Management also stresses the importance of maximizing return on equity through execution against a multi-year capital and operating plan, including managing and returning the potential value from future royalty revenues from the GSK financial collaboration to shareholders.